The biochemical diagnosis of acromegaly: revising the role of measurement of IGF-I and GH after glucose load in 5 questions

References

• Ben-Shlomo A, Melmed S. Acromegaly. Endocrinol Metab Clin North Am. 2008 Mar;371:101–122. https://doi.org/10.1016/j.ecl.2007.10.002
   PubMed Web of Science ®Google Scholar
• Lavrentaki A, Paluzzi A, Wass JA, et al. Epidemiology of acromegaly: review of population studies. Pituitary. 2017Feb;20(1):4–9. https://doi.org/10.1007/s11102-016-0754-x PubMed PMID: 27743174; PubMed Central PMCID: PMCPMC5334410
   PubMed Web of Science ®Google Scholar
• Esposito D, Ragnarsson O, Johannsson G, et al. Prolonged diagnostic delay in acromegaly is associated with increased morbidity and mortality. Eur J Endocrinol. 2020Jun;1826:523–531. https://doi.org/10.1530/EJE-20-0019 PubMed PMID: 32213651
   PubMed Web of Science ®Google Scholar
• Ioachimescu AG. Acromegaly: achieving timely diagnosis and improving outcomes by personalized care. Curr Opin Endocrinol Diabetes Obes. 2021 Aug 1;28(4):419–426. DOI:https://doi.org/10.1097/MED.0000000000000650. PubMed PMID: 34101652.
   Google Scholar
• Colao A, Grasso LFS, Giustina A, et al. Acromegaly. Nat Rev Dis Primers. 2019 Mar 21;5(1):20. PubMed PMID: 30899019. DOI:https://doi.org/10.1038/s41572-019-0071-6.
   Google Scholar
• Vilar L, Vilar CF, Lyra R, et al. Acromegaly: clinical features at diagnosis. Pituitary. 2017Feb;20(1):22–32. https://doi.org/10.1007/s11102-016-0772-8 PubMed PMID: 27812777; eng
   PubMed Web of Science ®Google Scholar
• Ribeiro de Oliveira Longo Schweizer J, Ribeiro-Oliveira A Jr., Bidlingmaier M. Growth hormone: isoforms, clinical aspects and assays interference. Clin Diabetes Endocrinol. 2018;4(1):18. PubMed PMID: 30181896; PubMed Central PMCID: PMCPMC6114276. DOI:https://doi.org/10.1186/s40842-018-0068-1
   PubMedGoogle Scholar
• Baumann G, MacCart JG. Growth hormone production by human pituitary glands in organ culture: evidence for predominant secretion of the single-chain 22,000 molecular weight form (isohormone B). J Clin Endocrinol Metab. 1982Oct;55(4):611–618. PubMed PMID: 7107808. https://doi.org/10.1210/jcem-55-4-611
   PubMed Web of Science ®Google Scholar
• Clemmons DR. Consensus statement on the standardization and evaluation of growth hormone and insulin-like growth factor assays. Clin Chem. 2011Apr;57(4):555–559. PubMed PMID: 21285256. https://doi.org/10.1373/clinchem.2010.150631
   PubMed Web of Science ®Google Scholar
• Baumann GP. Growth hormone isoforms. Growth Horm IGF Res. 2009 Aug;19(4):333–340. DOI: https://doi.org/10.1016/j.ghir.2009.04.011.
   PubMed Web of Science ®Google Scholar
• Hage M, Kamenicky P, Chanson P. Growth hormone response to oral glucose load: from normal to pathological conditions. Neuroendocrinology. 2019;108(3):244–255. PubMed PMID: 30685760. DOI:https://doi.org/10.1159/000497214
   PubMed Web of Science ®Google Scholar
• Lacroix MC, Guibourdenche J, Frendo JL, et al. Human placental growth hormone–a review. Placenta. 2002Apr;23Suppl A:S87–94. https://doi.org/10.1053/plac.2002.0811 PubMed PMID: 11978064
   PubMedGoogle Scholar
• Liao S, Vickers MH, Stanley JL, et al. Human Placental Growth Hormone Variant in Pathological Pregnancies. Endocrinology. 2018 May 1;159(5):2186–2198. PubMed PMID: 29659791; eng. DOI:https://doi.org/10.1210/en.2018-00037.
   Google Scholar
• Duncan E, Wass JA. Investigation protocol: acromegaly and its investigation. Clin Endocrinol (Oxf). 1999Mar;50(3):285–293. PubMed PMID: 10435052; eng. https://doi.org/10.1046/j.1365-2265.1999.00615.x
   PubMed Web of Science ®Google Scholar
• Hindmarsh PC, Matthews DR, Brain C, et al. The application of deconvolution analysis to elucidate the pulsatile nature of growth hormone secretion using a variable half-life of growth hormone. Clin Endocrinol (Oxf). 1990Jun;326:739–747. https://doi.org/10.1111/j.1365-2265.1990.tb00920.x PubMed PMID: 2383925; eng
   PubMed Web of Science ®Google Scholar
• Hartman ML, Iranmanesh A, Thorner MO, et al. Evaluation of pulsatile patterns of growth hormone release in humans: a brief review. Am J Hum Biol. 1993;5(6):603–614. PubMed PMID: 28548364; eng. DOI:https://doi.org/10.1002/ajhb.1310050603
   PubMed Web of Science ®Google Scholar
• Moller N, Vendelbo MH, Kampmann U, et al. Growth hormone and protein metabolism. Clin Nutr. 2009Dec;286:597–603. https://doi.org/10.1016/j.clnu.2009.08.015 PubMed PMID: 19773097; eng
   PubMedGoogle Scholar
• Møller N, Jørgensen JO. Effects of growth hormone on glucose, lipid, and protein metabolism in human subjects. Endocr Rev. 2009Apr;30(2):152–177. PubMed PMID: 19240267; eng. https://doi.org/10.1210/er.2008-0027
   PubMed Web of Science ®Google Scholar
• Caputo M, Pigni S, Agosti E, et al. Regulation of GH and GH Signaling by Nutrients. Cells. 2021 Jun 2;10(6):1376. PubMed PMID: 34199514; PubMed Central PMCID: PMCPMC8227158. eng. DOI:https://doi.org/10.3390/cells10061376.
   Google Scholar
• Hartman ML, Veldhuis JD, Thorner MO. Normal control of growth hormone secretion. Horm Res. 1993;40(1–3):37–47. PubMed PMID: 8300049. DOI:https://doi.org/10.1159/000183766
   PubMedGoogle Scholar
• Akirov A, Masri-Iraqi H, Dotan I, et al. The Biochemical Diagnosis of Acromegaly. J Clin Med. 2021 Mar 9;10(5):1147. PubMed PMID: 33803429; PubMed Central PMCID: PMCPMC7967116. DOI:https://doi.org/10.3390/jcm10051147.
   Google Scholar
• Bidlingmaier M, Friedrich N, Emeny RT, et al. Reference intervals for insulin-like growth factor-1 (igf-i) from birth to senescence: results from a multicenter study using a new automated chemiluminescence IGF-I immunoassay conforming to recent international recommendations. J Clin Endocrinol Metab. 2014May;995:1712–1721. https://doi.org/10.1210/jc.2013-3059 PubMed PMID: 24606072
   PubMed Web of Science ®Google Scholar
• Hwa V, Oh Y, Rosenfeld RG. The insulin-like growth factor-binding protein (IGFBP) superfamily. Endocr Rev. 1999Dec;20(6):761–787. PubMed PMID: 10605625; eng. https://doi.org/10.1210/edrv.20.6.0382
   PubMed Web of Science ®Google Scholar
• Allard JB, Duan C. IGF-binding proteins: why do they exist and why are there so many? Front Endocrinol (Lausanne). 2018;9:117. DOI:https://doi.org/10.3389/fendo.2018.00117. PubMed PMID: 29686648; PubMed Central PMCID: PMCPMC5900387. eng.
   PubMed Web of Science ®Google Scholar
• Bach LA. IGF-binding proteins. J Mol Endocrinol. 2018Jul;61(1):T11–T28. PubMed PMID: 29255001. https://doi.org/10.1530/JME-17-0254
   PubMed Web of Science ®Google Scholar
• Frystyk J, Vestbo E, Skjærbaek C, et al. Free insulin-like growth factors in human obesity. Metabolism. 1995;44:37–44.
   PubMed Web of Science ®Google Scholar
• Giustina A, Wehrenberg WB. Growth Hormone neuroregulation in diabetes mellitus. Trends Endocrinol Metab. 1994Mar;5(2):73–78. PubMed PMID: 18407191; eng. https://doi.org/10.1016/1043-2760(94)90005-1
   PubMedGoogle Scholar
• Brick DJ, Gerweck AV, Meenaghan E, et al. Determinants of IGF1 and GH across the weight spectrum: from anorexia nervosa to obesity. Eur J Endocrinol. 2010Aug;1632:185–191. https://doi.org/10.1530/eje-10-0365 PubMed PMID: 20501597; PubMed Central PMCID: PMCPMC2953770. eng
   PubMed Web of Science ®Google Scholar
• Kamenický P, Mazziotti G, Lombès M, et al. Growth hormone, insulin-like growth factor-1, and the kidney: pathophysiological and clinical implications. Endocr Rev. 2014Apr;352:234–281. https://doi.org/10.1210/er.2013-1071 PubMed PMID: 24423979; eng
   PubMed Web of Science ®Google Scholar
• Adamek A, Kasprzak A. Insulin-Like Growth Factor (IGF) system in liver diseases. Int J Mol Sci. 2018 Apr 27;19(5):1308. DOI:https://doi.org/10.3390/ijms19051308. PubMed PMID: 29702590; PubMed Central PMCID: PMCPMC5983723. eng.
   Google Scholar
• Southmayd EA, De Souza MJ. A summary of the influence of exogenous estrogen administration across the lifespan on the GH/IGF-1 axis and implications for bone health. Growth Horm IGF Res: Off J Growth Horm Res Soc Int IGF Res Soc. 2017 Feb;32:2–13. doi: https://doi.org/10.1016/j.ghir.2016.09.001. PubMed PMID: 27693042.
   PubMed Web of Science ®Google Scholar
• Valcavi R, Dieguez C, Zini M, et al. Influence of hyperthyroidism on growth hormone secretion. Clin Endocrinol (Oxf). 1993May;385:515–522. https://doi.org/10.1111/j.1365-2265.1993.tb00348.x PubMed PMID: 8330446
   PubMed Web of Science ®Google Scholar
• Szabo M. TRH and GRF stimulate release of growth hormone through different mechanisms. A J Physiol. 1986May;250(5 Pt 1):E512–7. PubMed PMID: 3010732; eng. https://doi.org/10.1152/ajpendo.1986.250.5.E512
   PubMedGoogle Scholar
• Miell JP, Taylor AM, Zini M, et al. Effects of hypothyroidism and hyperthyroidism on insulin-like growth factors (IGFs) and growth hormone- and IGF-binding proteins. J Clin Endocrinol Metab. 1993Apr;764:950–955. https://doi.org/10.1210/jcem.76.4.7682563 PubMed PMID: 7682563; eng
   PubMed Web of Science ®Google Scholar
• Van den Berghe G, de Zegher F, Veldhuis JD, et al. The somatotropic axis in critical illness: effect of continuous growth hormone (GH)-releasing hormone and GH-releasing peptide-2 infusion. J Clin Endocrinol Metab. 1997Feb;822:590–599. https://doi.org/10.1210/jcem.82.2.3736 PubMed PMID: 9024260; eng
   PubMedGoogle Scholar
• Chang FE, Dodds WG, Sullivan M, et al. The acute effects of exercise on prolactin and growth hormone secretion: comparison between sedentary women and women runners with normal and abnormal menstrual cycles. J Clin Endocrinol Metab. 1986Mar;623:551–556. https://doi.org/10.1210/jcem-62-3-551 PubMed PMID: 3080465
   PubMed Web of Science ®Google Scholar
• Thompson DL, Weltman JY, Rogol AD, et al. Cholinergic and opioid involvement in release of growth hormone during exercise and recovery. J Appl Physiol. 1985; 75(2):870–878. https://doi.org/10.1152/jappl.1993.75.2.870. PubMed PMID: 8226493 1993 Aug.
   Google Scholar
• Chennaoui M, Leger D, Gomez-Merino D. Sleep and the GH/IGF-1 axis: consequences and countermeasures of sleep loss/disorders. Sleep Med Rev. 2020Feb; 49: 101223.https://doi.org/10.1016/j.smrv.2019.101223 PubMed PMID: 31778943
   PubMed Web of Science ®Google Scholar
• Eakman GD, Dallas JS, Ponder SW, et al. The effects of testosterone and dihydrotestosterone on hypothalamic regulation of growth hormone secretion. J Clin Endocrinol Metab. 1996Mar;813:1217–1223. https://doi.org/10.1210/jcem.81.3.8772602 PubMed PMID: 8772602; eng
   PubMed Web of Science ®Google Scholar
• Ribeiro-Oliveira A Jr., Abrantes MM, Barkan AL. Complex rhythmicity and age dependence of growth hormone secretion are preserved in patients with acromegaly: further evidence for a present hypothalamic control of pituitary somatotropinomas. J Clin Endocrinol Metab. 2013Jul;98(7):2959–2966. PubMed PMID: 23640965; PubMed Central PMCID: PMCPMC3701276. eng. https://doi.org/10.1210/jc.2013-1581
   PubMed Web of Science ®Google Scholar
• Pincus SM, Keefe DL. Quantification of hormone pulsatility via an approximate entropy algorithm. A J Physiol. 1992May;262(5 Pt 1):E741–54. PubMed PMID: 1590385; eng. https://doi.org/10.1152/ajpendo.1992.262.5.E741
   PubMed Web of Science ®Google Scholar
• Pincus SM, Hartman ML, Roelfsema F, et al. Hormone pulsatility discrimination via coarse and short time sampling. A J Physiol. 1999Nov;2775:E948–57. https://doi.org/10.1152/ajpendo.1999.277.5.E948 PubMed PMID: 10567024; eng
   PubMedGoogle Scholar
• Roelfsema F, Pereira AM, Biermasz NR, et al. Hormone secretion by pituitary adenomas is characterized by increased disorderliness and spikiness but more regular pulsing. J Clin Endocrinol Metab. 2014Oct;9910:3836–3844. https://doi.org/10.1210/jc.2014-2363 PubMed PMID: 25014002; PubMed Central PMCID: PMCPMC4184075
   PubMed Web of Science ®Google Scholar
• Boguszewski CL, Johannsson G, Bengtsson BA, et al. Circulating non-22-kilodalton growth hormone isoforms in acromegalic men before and after transsphenoidal surgery. J Clin Endocrinol Metab. 1997May;825:1516–1521. https://doi.org/10.1210/jcem.82.5.3911 PubMed PMID: 9141543; eng
   PubMed Web of Science ®Google Scholar
• Irie M, Ueki M, Kishikawa Y, et al. 20K-GH and its use in detecting GH abuse. Growth Horm IGF Res. 2009 Aug;19(4):352–356. DOI: https://doi.org/10.1016/j.ghir.2009.04.013.
   PubMed Web of Science ®Google Scholar
• Arsene C, Schulze D, Rothke A, et al. Growth hormone isoform-differential mass spectrometry for doping control purposes. Drug Test Anal. 2018Jun;10(6):938–946. https://doi.org/10.1002/dta.2350 PubMed PMID: 29278456
   PubMed Web of Science ®Google Scholar
• Barkan AL, Beitins IZ, Kelch RP. Plasma insulin-like growth factor-I/somatomedin-C in acromegaly: correlation with the degree of growth hormone hypersecretion. J Clin Endocrinol Metab. 1988Jul;67(1):69–73. PubMed PMID: 2897974; eng. https://doi.org/10.1210/jcem-67-1-69
   PubMed Web of Science ®Google Scholar
• Katznelson L, Laws ER Jr., Melmed S, et al. Acromegaly: an endocrine society clinical practice guideline. J Clin Endocrinol Metab. 2014Nov;9911:3933–3951. https://doi.org/10.1210/jc.2014-2700 PubMed PMID: 25356808; eng
   PubMed Web of Science ®Google Scholar
• Frantz AG, Rabkin MT. HUMAN GROWTH HORMONE. CLINICAL MEASUREMENT, RESPONSE TO HYPOGLYCEMIA AND SUPPRESSION BY CORTICOSTEROIDS. N Engl J Med. 1964 Dec 31;271(27):1375–1381. DOI:https://doi.org/10.1056/nejm196412312712701. PubMed PMID: 14214653; eng.
   Google Scholar
• Frantz AG, Rabkin MT. Effects of estrogen and sex difference on secretion of human growth hormone. J Clin Endocrinol Metab. 1965Nov;25(11):1470–1480. PubMed PMID: 5843702; eng. https://doi.org/10.1210/jcem-25-11-1470
   PubMed Web of Science ®Google Scholar
• Hunter WM, Fonseka CC, Passmore R. The rôle of growth hormone in the mobilization of fuel for muscular exercise. Q J Exp Physiol cognate Med Sci. 1965 Oct;50(4):406–416. doi: https://doi.org/10.1113/expphysiol.1965.sp001806. PubMed PMID: 5177005; eng.
   PubMedGoogle Scholar
• Stimmler L, Snodgrass G. Plasma growth hormone response to intravenous glucagon administration. Arch Dis Child. 1971Oct;46(249):737. PubMed PMID: 5118078; PubMed Central PMCID: PMCPMC1647840. eng. https://doi.org/10.1136/adc.46.249.737-c
   PubMedGoogle Scholar
• Giustina A, Barkan A, Casanueva FF, et al. Criteria for cure of acromegaly: a consensus statement. J Clin Endocrinol Metab. 2000Feb;852:526–529. https://doi.org/10.1210/jcem.85.2.6363 PubMed PMID: 10690849; eng
   PubMed Web of Science ®Google Scholar
• Freda PU, Landman RE, Sundeen RE, et al. Gender and age in the biochemical assessment of cure of acromegaly. Pituitary. 2001Aug;43:163–171. https://doi.org/10.1023/a:1015314906972 PubMed PMID: 12138989; eng
   PubMedGoogle Scholar
• Roth J, Glick SM, Yalow RS, et al. Secretion of human growth hormone: physiologic and experimental modification. Metabolism. 1963 Jul;12:577–579. PubMed PMID: 13975314; eng
   PubMed Web of Science ®Google Scholar
• Peñalva A, Burguera B, Casabiell X, et al. Activation of cholinergic neurotransmission by pyridostigmine reverses the inhibitory effect of hyperglycemia on growth hormone (GH) releasing hormone-induced GH secretion in man: does acute hyperglycemia act through hypothalamic release of somatostatin? Neuroendocrinology. 1989May;495:551–554. https://doi.org/10.1159/000125166 PubMed PMID: 2566942; eng
   PubMed Web of Science ®Google Scholar
• Salmon WD Jr., Daughaday WH. A hormonally controlled serum factor which stimulates sulfate incorporation by cartilage in vitro. J Lab Clin Med. 1957 Jun;49(6):825–836. PubMed PMID: 13429201; eng.
   PubMed Web of Science ®Google Scholar
• Furlanetto RW, Underwood LE, Van Wyk JJ, et al. Estimation of somatomedin-C levels in normals and patients with pituitary disease by radioimmunoassay. J Clin Invest. 1977Sep;60(3):648–657. https://doi.org/10.1172/jci108816 PubMed PMID: 893668; PubMed Central PMCID: PMCPMC372409. eng
   PubMed Web of Science ®Google Scholar
• Derr RL, Cameron SJ, Golden SH. Pre-analytic considerations for the proper assessment of hormones of the hypothalamic-pituitary axis in epidemiological research. Eur J Epidemiol. 2006;21(3):217–226. PubMed PMID: 16547837; eng. DOI:https://doi.org/10.1007/s10654-006-0011-0
   PubMed Web of Science ®Google Scholar
• Chanson P, Arnoux A, Mavromati M, et al. Reference values for IGF-I serum concentrations: comparison of six immunoassays. J Clin Endocrinol Metab. 2016Sep;1019:3450–3458. https://doi.org/10.1210/jc.2016-1257 PubMed PMID: 27167056; PubMed Central PMCID: PMCPMC5054194. eng
   PubMed Web of Science ®Google Scholar
• Schilbach K, Bidlingmaier M. Laboratory investigations in the diagnosis and follow-up of GH-related disorders. Arch Endocrinol Metab. 2019Nov-Dec;63(6):618–629. PubMed PMID: 31939487. https://doi.org/10.20945/2359-3997000000192
   PubMed Web of Science ®Google Scholar
• Burns C, Rigsby P, Moore M, et al. The first international standard for insulin-like growth factor-1 (IGF-1) for immunoassay: preparation and calibration in an international collaborative study. Growth Horm IGF Res. 2009Oct;195:457–462. https://doi.org/10.1016/j.ghir.2009.02.002 PubMed PMID: 19303800; eng
   PubMed Web of Science ®Google Scholar
• Frystyk J, Freda P, Clemmons DR. The current status of IGF-I assays–a 2009 update. Growth Horm IGF Res: Off J Growth Horm Res Soc Int IGF Res Soc. 2010 Feb;20(1):8–18. doi: https://doi.org/10.1016/j.ghir.2009.09.004. PubMed PMID: 19818658; PubMed Central PMCID: PMCPMC7748085. eng.
   PubMed Web of Science ®Google Scholar
• Kwan AY, Hartman ML. IGF-I measurements in the diagnosis of adult growth hormone deficiency. Pituitary. 2007;10(2):151–157. PubMed PMID: 17429593; eng. DOI:https://doi.org/10.1007/s11102-007-0028-8
   PubMed Web of Science ®Google Scholar
• Hymer WC, Kennett MJ, Maji SK, et al. Bioactive growth hormone in humans: controversies, complexities and concepts. Growth Horm IGF Res: Off J Growth Horm Res Soc Int IGF Res Soc. 2020 Feb;50:9–22. doi: https://doi.org/10.1016/j.ghir.2019.11.003. PubMed PMID: 31809882; eng.
   PubMed Web of Science ®Google Scholar
• Baumann G. Metabolism of growth hormone (GH) and different molecular forms of GH in biological fluids. Horm Res. 1991;36(Suppl 1):5–10. PubMedPMID: 1806486; eng. DOI:https://doi.org/10.1159/000182179
   PubMedGoogle Scholar
• Bidlingmaier F, Geilenkeuser WJ, Kruse R, et al. Our experience with quality control in current growth hormone assays. Horm Res. 1991;36(Suppl 1):1–4. PubMed PMID: 1806476; eng. DOI:https://doi.org/10.1159/000182178
   PubMedGoogle Scholar
• Markkanen H, Pekkarinen T, Välimäki MJ, et al. Effect of sex and assay method on serum concentrations of growth hormone in patients with acromegaly and in healthy controls. Clin Chem. 2006Mar;523:468–473. https://doi.org/10.1373/clinchem.2005.060236 PubMed PMID: 16439607; eng
   PubMed Web of Science ®Google Scholar
• Bidlingmaier M, Freda PU. Measurement of human growth hormone by immunoassays: current status, unsolved problems and clinical consequences. Growth Horm IGF Res. 2010 Feb;20(1):19–25. DOI: https://doi.org/10.1016/j.ghir.2009.09.005.
   PubMed Web of Science ®Google Scholar
• Manolopoulou J, Alami Y, Petersenn S, et al. Automated 22-kD growth hormone-specific assay without interference from pegvisomant. Clin Chem. 2012Oct;5810:1446–1456. https://doi.org/10.1373/clinchem.2012.188128 PubMed PMID: 22908135
   PubMed Web of Science ®Google Scholar
• Schilbach K, Strasburger CJ, Bidlingmaier M. Biochemical investigations in diagnosis and follow up of acromegaly. Pituitary. 2017Feb;20(1):33–45. PubMed PMID: 28168377. https://doi.org/10.1007/s11102-017-0792-z
   PubMed Web of Science ®Google Scholar
• Freda PU. Pitfalls in the biochemical assessment of acromegaly. Pituitary. 2003;6(3):135–140. PubMed PMID: 14971738; eng. DOI:https://doi.org/10.1023/b:pitu.0000011174.79946.10
   PubMedGoogle Scholar
• Arafat AM, Möhlig M, Weickert MO, et al. Growth hormone response during oral glucose tolerance test: the impact of assay method on the estimation of reference values in patients with acromegaly and in healthy controls, and the role of gender, age, and body mass index. J Clin Endocrinol Metab. 2008Apr;934:1254–1262. https://doi.org/10.1210/jc.2007-2084 PubMed PMID: 18171702; eng
   PubMed Web of Science ®Google Scholar
• Wieringa GE, Sturgeon CM, Trainer PJ. The harmonisation of growth hormone measurements: taking the next steps. Clin Chim Acta. 2014 May 15;432:68–71. DOI:https://doi.org/10.1016/j.cca.2014.01.014. PubMed PMID: 24509000.
   Google Scholar
• Carrozza C, Lapolla R, Canu G, et al. Human growth hormone (GH) immunoassay: standardization and clinical implications. Clin Chem Lab Med. 2011May;495:851–853. https://doi.org/10.1515/cclm.2011.138 PubMed PMID: 21361855; eng
   PubMed Web of Science ®Google Scholar
• Kopchick JJ, Parkinson C, Stevens EC, et al. Growth hormone receptor antagonists: discovery, development, and use in patients with acromegaly. Endocr Rev. 2002Oct;235:623–646. https://doi.org/10.1210/er.2001-0022 PubMed PMID: 12372843; eng
   PubMed Web of Science ®Google Scholar
• Paisley AN, Hayden K, Ellis A, et al. Pegvisomant interference in GH assays results in underestimation of GH levels. Eur J Endocrinol. 2007Mar;1563:315–319. https://doi.org/10.1530/eje.1.02341 PubMed PMID: 17322491; eng
   PubMed Web of Science ®Google Scholar
• Giustina A, Ambrosio MR, Beck Peccoz P, et al. Use of pegvisomant in acromegaly. an Italian society of endocrinology guideline. J Endocrinol Invest. 2014Oct;3710:1017–1030. https://doi.org/10.1007/s40618-014-0146-x PubMed PMID: 25245336; PubMed Central PMCID: PMCPMC4182612
   PubMed Web of Science ®Google Scholar
• Trainer PJ, Drake WM, Katznelson L, et al. Treatment of acromegaly with the growth hormone-receptor antagonist pegvisomant. N Engl J Med. 2000 Apr 20;342(16):1171–1177. PubMed PMID: 10770982. DOI:https://doi.org/10.1056/NEJM200004203421604.
   Google Scholar
• Colao A, Pivonello R, Auriemma RS, et al. Efficacy of 12-month treatment with the GH receptor antagonist pegvisomant in patients with acromegaly resistant to long-term, high-dose somatostatin analog treatment: effect on IGF-I levels, tumor mass, hypertension and glucose tolerance. Eur J Endocrinol. 2006Mar;1543:467–477. https://doi.org/10.1530/eje.1.02112 PubMed PMID: 16498061
   PubMed Web of Science ®Google Scholar
• Ebdrup L, Fisker S, Sørensen HH, et al. Variety in growth hormone determinations due to use of different immunoassays and to the interference of growth hormone-binding protein. Horm Res. 1999;51 Suppl 1:20–26. PubMed PMID: 10393487; eng. DOI:https://doi.org/10.1159/000053131
   PubMedGoogle Scholar
• Conway-Campbell BL, Brooks AJ, Robinson PJ, et al. The extracellular domain of the growth hormone receptor interacts with coactivator activator to promote cell proliferation. Mol Endocrinol. 2008Sep;229:2190–2202. https://doi.org/10.1210/me.2008-0128 PubMed PMID: 18635665; PubMed Central PMCID: PMCPMC5419461
   PubMedGoogle Scholar
• Baumann G. Growth hormone binding protein 2001. J Pediatr Endocrinol Metab. 2001Apr;14(4):355–375. PubMed PMID: 11327370; eng. https://doi.org/10.1515/jpem.2001.14.4.355
   PubMed Web of Science ®Google Scholar
• Popii V, Baumann G. Laboratory measurement of growth hormone. Clin Chim Acta. 2004Dec;350(1–2):1–16. PubMed PMID: 15530455; eng. https://doi.org/10.1016/j.cccn.2004.06.007
   PubMed Web of Science ®Google Scholar
• Jan T, Shaw MA, Baumann G. Effects of growth hormone-binding proteins on serum growth hormone measurements. J Clin Endocrinol Metab. 1991Feb;72(2):387–391. PubMed PMID: 1991809; eng. https://doi.org/10.1210/jcem-72-2-387
   PubMed Web of Science ®Google Scholar
• Hansen TK, Fisker S, Hansen B, et al. Impact of GHBP interference on estimates of GH and GH pharmacokinetics. Clin Endocrinol (Oxf). 2002Dec;576:779–786. https://doi.org/10.1046/j.1365-2265.2002.01668.x PubMed PMID: 12460328; eng
   PubMed Web of Science ®Google Scholar
• Muhammad A, Neggers SJ, van der Lely AJ. Pregnancy and acromegaly. Pituitary. 2017Feb;20(1):179–184. PubMed PMID: 27568329; PubMed Central PMCID: PMCPMC5334433. https://doi.org/10.1007/s11102-016-0740-3
   PubMed Web of Science ®Google Scholar
• Hannon AM, O’Shea T, Thompson CA, et al. Pregnancy in acromegaly is safe and is associated with improvements in IGF-1 concentrations. Eur J Endocrinol. 2019 Apr 1;180(4):K21–k29. PubMed PMID: 30620709; eng. DOI:https://doi.org/10.1530/eje-18-0688.
   Google Scholar
• Barrios V, Chowen JA, Martin-Rivada A, et al. Pregnancy-associated plasma protein (PAPP)-A2 in physiology and disease. Cells. 2021 Dec 18;10(12):3576. PubMed PMID: 34944082; PubMed Central PMCID: PMCPMC8700087. DOI:https://doi.org/10.3390/cells10123576.
   Google Scholar
• Earll JM. Glucose suppression of serum growth hormone in the diagnosis of acromegaly. JAMA. 1967;201(8):628.
   PubMedGoogle Scholar
• Boden G, Soeldner JS, Steinke J, et al. Serum human growth hormone (HGH) response to IV glucose: diagnosis of acromegaly in females and males. Metabolism. 1968;17(1):1–9.
   PubMed Web of Science ®Google Scholar
• Arafat AM, Müller L, Möhlig M, et al. Comparison of oral glucose tolerance test (OGTT) 100 g with OGTT 75 g for evaluation of acromegalic patients and the impact of gender on test reproducibility. Clin Endocrinol (Oxf). 2011Nov;755:685–691. https://doi.org/10.1111/j.1365-2265.2011.04108.x PubMed PMID: 21575028; eng
   PubMed Web of Science ®Google Scholar
• Schilbach K, Gar C, Lechner A, et al. Determinants of the growth hormone nadir during oral glucose tolerance test in adults. Eur J Endocrinol. 2019Jul;1811:55–67. https://doi.org/10.1530/EJE-19-0139 PubMed PMID: 31096183
   PubMed Web of Science ®Google Scholar
• Hattori N, Shimatsu A, Kato Y, et al. Growth hormone responses to oral glucose loading measured by highly sensitive enzyme immunoassay in normal subjects and patients with glucose intolerance and acromegaly. J Clin Endocrinol Metab. 1990Mar;70 (3):771–776. https://doi.org/10.1210/jcem-70-3-771 PubMed PMID: 2106529; eng
   PubMed Web of Science ®Google Scholar
• De Marinis L, Mancini A, Bianchi A, et al. Preoperative growth hormone response to thyrotropin-releasing hormone and oral glucose tolerance test in acromegaly: a retrospective evaluation of 50 patients. Metabolism. 2002May;515:616–621. https://doi.org/10.1053/meta.2002.32017 PubMed PMID: 11979395; eng
   PubMed Web of Science ®Google Scholar
• von Werder K. Biochemical evidence supporting the Cortina criteria. J Endocrinol Invest. 2005;28(11 Suppl International):81–83. PubMed PMID: 16625853; eng.
   PubMedGoogle Scholar
• Espinosa-de-los-monteros AL, Mercado M, Sosa E, et al. Changing patterns of insulin-like growth factor-I and glucose-suppressed growth hormone levels after pituitary surgery in patients with acromegaly. J Neurosurg. 2002Aug;972:287–292. https://doi.org/10.3171/jns.2002.97.2.0287 PubMed PMID: 12186455; eng
   PubMed Web of Science ®Google Scholar
• Biochemical assessment and long-term monitoring in patients with acromegaly: statement from a joint consensus conference of the growth hormone research society and the pituitary society. J Clin Endocrinol Metab. 2004Jul; 89(7):3099–3102. DOI:https://doi.org/10.1210/jc.2003-031138 PubMed PMID: 15240576; eng.
   PubMed Web of Science ®Google Scholar
• Gullu S, Keles H, Delibasi T, et al. Remission criteria for the follow-up of patients with acromegaly. Eur J Endocrinol. 2004Apr;150(4):465–471. https://doi.org/10.1530/eje.0.1500465 PubMed PMID: 15080775; eng
   PubMed Web of Science ®Google Scholar
• Serri O, Beauregard C, Hardy J. Long-term biochemical status and disease-related morbidity in 53 postoperative patients with acromegaly. J Clin Endocrinol Metab. 2004Feb;89(2):658–661. PubMed PMID: 14764777; eng. https://doi.org/10.1210/jc.2003-030915
   PubMed Web of Science ®Google Scholar
• Minuto F, Resmini E, Boschetti M, et al. Assessment of disease activity in acromegaly by means of a single blood sample: comparison of the 120th minute postglucose value with spontaneous GH secretion and with the IGF system. Clin Endocrinol (Oxf). 2004Jul;611:138–144. https://doi.org/10.1111/j.1365-2265.2004.02064.x PubMed PMID: 15212656; eng
   PubMed Web of Science ®Google Scholar
• Verrua E, Filopanti M, Ronchi CL, et al. GH response to oral glucose tolerance test: a comparison between patients with acromegaly and other pituitary disorders. J Clin Endocrinol Metab. 2011Jan;961:E83–8. https://doi.org/10.1210/jc.2010-1115 PubMed PMID: 20962023
   PubMed Web of Science ®Google Scholar
• Bancos I, Algeciras-Schimnich A, Woodmansee WW, et al. Determination of nadir growth hormone concentration cutoff in patients with acromegaly. Endocr Pract. 2013Nov-Dec;196:937–945. https://doi.org/10.4158/ep12435.or PubMed PMID: 23807518; eng
   PubMed Web of Science ®Google Scholar
• Cozzi R, Ambrosio MR, Attanasio R, et al. Italian association of clinical endocrinologists (AME) and Italian AACE chapter position statement for clinical practice: acromegaly - part 1: diagnostic and clinical issues. Endocr Metab Immune Disord Drug Targets. 2020;20(8):1133–1143. PubMed PMID: 31985386; PubMed Central PMCID: PMCPMC7579251. eng. DOI:https://doi.org/10.2174/1871530320666200127103320
   PubMedGoogle Scholar
• Freda PU, Reyes CM, Nuruzzaman AT, et al. Basal and glucose-suppressed GH levels less than 1 microg/L in newly diagnosed acromegaly. Pituitary. 2003;6(4):175–180. PubMed PMID: 15237928; eng. DOI:https://doi.org/10.1023/b:pitu.0000023424.72021.e2
   PubMedGoogle Scholar
• Giustina A, Chanson P, Bronstein MD, et al. A consensus on criteria for cure of acromegaly. J Clin Endocrinol Metab. 2010Jul;957:3141–3148. https://doi.org/10.1210/jc.2009-2670 PubMed PMID: 20410227
   PubMed Web of Science ®Google Scholar
• Katznelson L, Atkinson JL, Cook DM, et al. American association of clinical endocrinologists medical guidelines for clinical practice for the diagnosis and treatment of acromegaly–2011 update: executive summary. Endocr Pract. 2011Jul-Aug;174:636–646. https://doi.org/10.4158/ep.17.4.636 PubMed PMID: 21846619; eng
   PubMed Web of Science ®Google Scholar
• Monaghan PJ, Trainer PJ. Determinants of the growth hormone nadir during oral glucose tolerance test in adults. Eur J Endocrinol. 2019Nov;181(5):C17–c20. PubMed PMID: 31480015; eng. https://doi.org/10.1530/eje-19-0661
   PubMed Web of Science ®Google Scholar
• Rosário PW, Furtado MS. Growth hormone after oral glucose overload: revision of reference values in normal subjects. Arq Bras Endocrinol Metabol. 2008 Oct;52(7):1139–1144. DOI: https://doi.org/10.1590/s0004-27302008000700010.
   PubMedGoogle Scholar
• Giustina A, Barkhoudarian G, Beckers A, et al. Multidisciplinary management of acromegaly: a consensus. Rev Endocr Metab Disord. 2020Dec;214:667–678. https://doi.org/10.1007/s11154-020-09588-z PubMed PMID: 32914330; PubMed Central PMCID: PMCPMC7942783. eng
   PubMed Web of Science ®Google Scholar
• Deutschbein T, Bidlingmaier M, Schopohl J, et al. Anthropometric factors have significant influence on the outcome of the GHRH-arginine test: establishment of normative data for an automated immunoassay specifically measuring 22 kDa human growth hormone. Eur J Endocrinol. 2017Mar;1763:273–281. https://doi.org/10.1530/eje-16-0668 PubMed PMID: 27932410; eng
   PubMed Web of Science ®Google Scholar
• Colao A, Pivonello R, Auriemma RS, et al. Growth hormone nadir during oral glucose load depends on waist circumference, gender and age: normative data in 231 healthy subjects. Clin Endocrinol (Oxf). 2011Feb;742:234–240. https://doi.org/10.1111/j.1365-2265.2010.03896.x PubMed PMID: 21054474; eng
   PubMed Web of Science ®Google Scholar
• Martha PM Jr., Rogol AD, Veldhuis JD, et al. Alterations in the pulsatile properties of circulating growth hormone concentrations during puberty in boys. J Clin Endocrinol Metab. 1989Sep;693:563–570. https://doi.org/10.1210/jcem-69-3-563 PubMed PMID: 2760171
   PubMed Web of Science ®Google Scholar
• Evain-Brion D, Garnier P, Schimpff RM, et al. Growth hormone response to thyrotropin-releasing hormone and oral glucose-loading tests in tall children and adolescents. J Clin Endocrinol Metab. 1983Mar;563:429–432. https://doi.org/10.1210/jcem-56-3-429 PubMed PMID: 6401755; eng
   PubMed Web of Science ®Google Scholar
• Misra M, Cord J, Prabhakaran R, et al. Growth hormone suppression after an oral glucose load in children. J Clin Endocrinol Metab. 2007Dec;9212:4623–4629. https://doi.org/10.1210/jc.2007-1244 PubMed PMID: 17878248
   PubMed Web of Science ®Google Scholar
• Russell-Aulet M, Jaffe CA, Demott-Friberg R, et al. In vivo semiquantification of hypothalamic growth hormone-releasing hormone (GHRH) output in humans: evidence for relative GHRH deficiency in aging. J Clin Endocrinol Metab. 1999Oct;8410:3490–3497. https://doi.org/10.1210/jcem.84.10.6063 PubMed PMID: 10522985; eng
   PubMed Web of Science ®Google Scholar
• Colao A, Pivonello R, Cavallo LM, et al. Age changes the diagnostic accuracy of mean profile and nadir growth hormone levels after oral glucose in postoperative patients with acromegaly. Clin Endocrinol (Oxf). 2006Aug;652:250–256. https://doi.org/10.1111/j.1365-2265.2006.02584.x PubMed PMID: 16886969; eng
   PubMed Web of Science ®Google Scholar
• Chapman IM, Hartman ML, Straume M, et al. Enhanced sensitivity growth hormone (GH) chemiluminescence assay reveals lower postglucose nadir GH concentrations in men than women. J Clin Endocrinol Metab. 1994Jun;786:1312–1319. https://doi.org/10.1210/jcem.78.6.8200931 PubMed PMID: 8200931; eng
   PubMed Web of Science ®Google Scholar
• Faria AC, Bekenstein LW, Booth RA Jr., et al. Pulsatile growth hormone release in normal women during the menstrual cycle. Clin Endocrinol (Oxf). 1992Jun;366:591–596. https://doi.org/10.1111/j.1365-2265.1992.tb02270.x PubMed PMID: 1424184; eng
   PubMed Web of Science ®Google Scholar
• Jaffe CA, Ocampo-Lim B, Guo W, et al. Regulatory mechanisms of growth hormone secretion are sexually dimorphic. J Clin Invest. 1998 Jul 1;102(1):153–164. PubMed PMID: 9649569; PubMed Central PMCID: PMCPMC509077. DOI:https://doi.org/10.1172/JCI2908.
   Google Scholar
• Dawson-Hughes B, Stern D, Goldman J, et al. Regulation of growth hormone and somatomedin-C secretion in postmenopausal women: effect of physiological estrogen replacement. J Clin Endocrinol Metab. 1986Aug;632:424–432. https://doi.org/10.1210/jcem-63-2-424 PubMed PMID: 3088024
   PubMed Web of Science ®Google Scholar
• Weissberger AJ, Ho KK, Lazarus L. Contrasting effects of oral and transdermal routes of estrogen replacement therapy on 24-hour growth hormone (GH) secretion, insulin-like growth factor I, and GH-binding protein in postmenopausal women. J Clin Endocrinol Metab. 1991Feb;72(2):374–381. PubMed PMID: 1991807; eng. https://doi.org/10.1210/jcem-72-2-374
   PubMed Web of Science ®Google Scholar
• Ohlsson C, Mohan S, Sjögren K, et al. The role of liver-derived insulin-like growth factor-I. Endocr Rev. 2009Aug;30(5):494–535. https://doi.org/10.1210/er.2009-0010 PubMed PMID: 19589948; PubMed Central PMCID: PMCPMC2759708. eng
   PubMed Web of Science ®Google Scholar
• Asplin CM, Faria AC, Carlsen EC, et al. Alterations in the pulsatile mode of growth hormone release in men and women with insulin-dependent diabetes mellitus. J Clin Endocrinol Metab. 1989Aug;692:239–245. https://doi.org/10.1210/jcem-69-2-239 PubMed PMID: 2753972; eng
   PubMed Web of Science ®Google Scholar
• Ismail IS, Scanlon MF, Peters JR. Cholinergic control of growth hormone (GH) responses to GH-releasing hormone in insulin dependent diabetics: evidence for attenuated hypothalamic somatostatinergic tone and decreased GH autofeedback. Clin Endocrinol (Oxf). 1993Feb;38(2):149–157. PubMed PMID: 8094648; eng. https://doi.org/10.1111/j.1365-2265.1993.tb00987.x
   PubMed Web of Science ®Google Scholar
• Giustina A, Veldhuis JD. Pathophysiology of the neuroregulation of growth hormone secretion in experimental animals and the human. Endocr Rev. 1998Dec;19(6):717–797. PubMed PMID: 9861545; eng. https://doi.org/10.1210/edrv.19.6.0353
   PubMed Web of Science ®Google Scholar
• Cozzi R, Baldelli R, Colao A, et al. AME Position Statement on clinical management of acromegaly. J Endocrinol Invest. 2009;32(6 Suppl):2–25. PubMed PMID: 19923883; eng.
   PubMedGoogle Scholar
• Rosario PW, Calsolari MR. Safety and specificity of the growth hormone suppression test in patients with diabetes. Endocrine. 2015Feb;48(1):329–333. PubMed PMID: 24833548; eng. https://doi.org/10.1007/s12020-014-0282-2
   PubMed Web of Science ®Google Scholar
• Dobri G, Niwattisaiwong S, Bena JF, et al. Is GH nadir during OGTT a reliable test for diagnosis of acromegaly in patients with abnormal glucose metabolism? Endocrine. 2019Apr;641:139–146. https://doi.org/10.1007/s12020-018-1805-z PubMed PMID: 30415402; eng
   PubMed Web of Science ®Google Scholar
• Chestnut RE, Quarmby V. Evaluation of total IGF-I assay methods using samples from type I and type II diabetic patients. J Immunol Methods. 2002 Jan 1;259(1–2):11–24. DOI:https://doi.org/10.1016/s0022-1759(01)00478-1. PubMed PMID: 11730837; eng.
   Google Scholar
• de Pablos-velasco P, Venegas EM, C ÁE, et al. Diagnosis, treatment and follow-up of patients with acromegaly in a clinical practice setting in Spain: the ACROPRAXIS program Delphi survey. Pituitary. 2020Apr;232:129–139. https://doi.org/10.1007/s11102-019-01012-3 PubMed PMID: 31823249; PubMed Central PMCID: PMCPMC7066268. eng
   PubMedGoogle Scholar
• Grottoli S, Razzore P, Gaia D, et al. Three-hour spontaneous GH secretion profile is as reliable as oral glucose tolerance test for the diagnosis of acromegaly. J Endocrinol Invest. 2003Feb;262:123–127. https://doi.org/10.1007/bf03345139 PubMed PMID: 12739738; eng
   PubMed Web of Science ®Google Scholar
• Regazzo D, Losa M, Albiger NM, et al. The GIP/GIPR axis is functionally linked to GH-secretion increase in a significant proportion of gsp(-) somatotropinomas. Eur J Endocrinol. 2017May;1765:543–553. https://doi.org/10.1530/EJE-16-0831 PubMed PMID: 28179449
   PubMed Web of Science ®Google Scholar
• Scaroni C, Albiger N, Daniele A, et al. Paradoxical GH increase during OGTT is associated with first-generation somatostatin analog responsiveness in acromegaly. J Clin Endocrinol Metab. 2019 Mar 1;104(3):856–862. PubMed PMID: 30285115; eng. DOI:https://doi.org/10.1210/jc.2018-01360.
   Google Scholar
• Mukai K, Otsuki M, Tamada D, et al. Clinical Characteristics of Acromegalic Patients With Paradoxical GH Response to Oral Glucose Load. J Clin Endocrinol Metab. 2019 May 1;104(5):1637–1644. PubMed PMID: 30476255. DOI:https://doi.org/10.1210/jc.2018-00975.
   Google Scholar
• Atquet V, Alexopoulou O, Maiter D. Characteristics and treatment responsiveness of patients with acromegaly and a paradoxical GH increase to oral glucose load. Eur J Endocrinol. 2021 Jul 1;185(2):313–321. DOI:https://doi.org/10.1530/EJE-21-0324. PubMed PMID: 34085950.
   Google Scholar
• Hage M, Janot C, Salenave S, et al. MANAGEMENT OF ENDOCRINE DISEASE: etiology and outcome of acromegaly in patients with a paradoxical GH response to glucose. Eur J Endocrinol. 2021 May 10;184(6):R261–R268. PubMed PMID: 33830942. DOI:https://doi.org/10.1530/EJE-20-1448.
   Google Scholar
• Dimaraki EV, Jaffe CA, DeMott-Friberg R, et al. Acromegaly with apparently normal GH secretion: implications for diagnosis and follow-up. J Clin Endocrinol Metab. 2002Aug;878:3537–3542. https://doi.org/10.1210/jcem.87.8.8658 PubMed PMID: 12161471; eng
   PubMed Web of Science ®Google Scholar
• Mercado M, Espinosa de Los Monteros AL, Sosa E, et al. Clinical-biochemical correlations in acromegaly at diagnosis and the real prevalence of biochemically discordant disease. Horm Res. 2004;62(6):293–299. PubMed PMID: 15542931; eng. DOI:https://doi.org/10.1159/000082032
   PubMedGoogle Scholar
• Machado EO, Taboada GF, Neto LV, et al. Prevalence of discordant GH and IGF-I levels in acromegalics at diagnosis, after surgical treatment and during treatment with octreotide LAR. Growth Horm IGF Res. 2008 Oct;18(5):389–393. DOI: https://doi.org/10.1016/j.ghir.2008.02.001.
   PubMed Web of Science ®Google Scholar
• Espinosa de Los Monteros AL, Sosa-Eroza E, Gonzalez B, et al. Prevalence, clinical and biochemical spectrum, and treatment outcome of acromegaly with normal basal GH at diagnosis. J Clin Endocrinol Metab. 2018 Oct 1;103(10):3919–3924. PubMed PMID: 30060172. DOI:https://doi.org/10.1210/jc.2018-01113.
   Google Scholar
• Ribeiro-Oliveira A Jr., Faje AT, Barkan AL. Limited utility of oral glucose tolerance test in biochemically active acromegaly. Eur J Endocrinol. 2011Jan;164(1):17–22. PubMed PMID: 20926592; eng. https://doi.org/10.1530/eje-10-0744
   PubMed Web of Science ®Google Scholar
• Butz LB, Sullivan SE, Chandler WF, et al. “Micromegaly”: an update on the prevalence of acromegaly with apparently normal GH secretion in the modern era. Pituitary. 2016Dec;196:547–551. https://doi.org/10.1007/s11102-016-0735-0 PubMed PMID: 27497970; eng
   PubMed Web of Science ®Google Scholar
• Carosi G, Mangone A, Sala E, et al. Clinical and hormonal findings in patients presenting with high IGF-1 and growth hormone suppression after oral glucose load: a retrospective cohort study. Eur J Endocrinol. 2021 Jul 1;185(2):289–297. PubMed PMID: 34081617; PubMed Central PMCID: PMCPMC8284905. DOI:https://doi.org/10.1530/EJE-21-0024.
   Google Scholar
• Freda PU. Monitoring of acromegaly: what should be performed when GH and IGF-1 levels are discrepant? Clin Endocrinol (Oxf). 2009Aug;71(2):166–170. PubMed PMID: 19226264; PubMed Central PMCID: PMCPMC3654652. https://doi.org/10.1111/j.1365-2265.2009.03556.x
   PubMed Web of Science ®Google Scholar
• Fleseriu M, Biller BMK, Freda PU, et al. A Pituitary Society update to acromegaly management guidelines. Pituitary. 2021Feb;241:1–13. https://doi.org/10.1007/s11102-020-01091-7 PubMed PMID: 33079318; PubMed Central PMCID: PMCPMC7864830
   PubMed Web of Science ®Google Scholar
• Kristof RA, Neuloh G, Redel L, et al. Reliability of the oral glucose tolerance test in the early postoperative assessment of acromegaly remission. J Neurosurg. 2002Dec;976:1282–1286. https://doi.org/10.3171/jns.2002.97.6.1282 PubMed PMID: 12507124; eng
   PubMed Web of Science ®Google Scholar
• Feelders RA, Bidlingmaier M, Strasburger CJ, et al. Postoperative evaluation of patients with acromegaly: clinical significance and timing of oral glucose tolerance testing and measurement of (free) insulin-like growth factor I, acid-labile subunit, and growth hormone-binding protein levels. J Clin Endocrinol Metab. 2005Dec;90(12):6480–6489. https://doi.org/10.1210/jc.2005-0901 PubMed PMID: 16159936; eng
   PubMed Web of Science ®Google Scholar
• Kim EH, Oh MC, Lee EJ, et al. Predicting long-term remission by measuring immediate postoperative growth hormone levels and oral glucose tolerance test in acromegaly. Neurosurgery. 2011;70(5):1106–1113.
   Web of Science ®Google Scholar
• Rotermund R, Burkhardt T, Rohani Z, et al. Value of early postoperative random growth hormone levels and nadir growth hormone levels after oral glucose tolerance testing in acromegaly. Growth Horm IGF Res. 2018 Aug;41:64–70. DOI: https://doi.org/10.1016/j.ghir.2018.03.002.
   PubMed Web of Science ®Google Scholar
• Freda PU, Nuruzzaman AT, Reyes CM, et al. Significance of “abnormal” nadir growth hormone levels after oral glucose in postoperative patients with acromegaly in remission with normal insulin-like growth factor-I levels. J Clin Endocrinol Metab. 2004Feb;892:495–500. https://doi.org/10.1210/jc.2003-031316 PubMed PMID: 14764751; eng
   PubMed Web of Science ®Google Scholar
• Ronchi CL, Varca V, Giavoli C, et al. Long-term evaluation of postoperative acromegalic patients in remission with previous and newly proposed criteria. J Clin Endocrinol Metab. 2005Mar;90(3):1377–1382. https://doi.org/10.1210/jc.2004-1974 PubMed PMID: 15585548; eng
   PubMed Web of Science ®Google Scholar
• Ronchi CL, Arosio M, Rizzo E, et al. Adequacy of current postglucose GH nadir limit (< 1 microg/l) to define long-lasting remission of acromegalic disease. Clin Endocrinol (Oxf). 2007Apr;664:538–542. https://doi.org/10.1111/j.1365-2265.2007.02769.x PubMed PMID: 17371472; eng
   PubMed Web of Science ®Google Scholar
• Freda PU, Bruce JN, Reyes-Vidal C, et al. Prognostic value of nadir GH levels for long-term biochemical remission or recurrence in surgically treated acromegaly. Pituitary. 2021Apr;242:170–183. https://doi.org/10.1007/s11102-020-01094-4 PubMed PMID: 33124000; PubMed Central PMCID: PMCPMC7969360. eng
   PubMed Web of Science ®Google Scholar
• Sakata K, Nagata Y, Takeshige N, et al. Early postoperative prediction of both disease remission and long-term disease control in acromegaly using the oral glucose tolerance test. Hormones (Athens). 2021Sep;20(3):515–526. https://doi.org/10.1007/s42000-021-00281-7 PubMed PMID: 33738782; eng
   PubMedGoogle Scholar
• Jung IH, Choi S, Ku CR, et al. Revisiting the role of insulin-like growth factor-1 measurement after surgical treatment of acromegaly. J Clin Endocrinol Metab. 2021 Jun 16;106(7):e2589–e2599. PubMed PMID: 33738470. DOI:https://doi.org/10.1210/clinem/dgab186.
   Google Scholar
• Shin MS, Yu JH, Choi JH, et al. Long-term changes in serum IGF-1 levels after successful surgical treatment of growth hormone-secreting pituitary adenoma. Neurosurgery. 2013 Sep;73(3):473–479. DOI:https://doi.org/10.1227/01.neu.0000431480.87160.84. quiz 479. doi: PubMed PMID: 23728452.
   PubMed Web of Science ®Google Scholar
• Melmed S, Bronstein MD, Chanson P, et al. A consensus statement on acromegaly therapeutic outcomes. Nat Rev Endocrinol. 2018Sep;149:552–561. https://doi.org/10.1038/s41574-018-0058-5 PubMed PMID: 30050156; PubMed Central PMCID: PMCPMC7136157
   PubMed Web of Science ®Google Scholar